CD8A and neoplasm: The latest small molecule inhibitor, BI 2536, inhibits the proliferation of ovarian cancer cells, triggers cell cycle halt at the G2/M phase, and accumulates CD8+ T lymphocyte cells at tumor sites via initiating pyroptosis in ovarian cancer through the caspase 3/GSDME pathway.43